LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia

Chao Guo,Ya-yue Gao,Qian-qian Ju,Chun-xia Zhang,Ming Gong,Zhen-ling Li
DOI: https://doi.org/10.1186/s12885-020-07331-0
IF: 4.638
2020-09-03
BMC Cancer
Abstract:Abstract Background Long noncoding RNAs (lncRNA) play a role in leukemogenesis, maintenance, development, and therapeutic resistance of AML. While few studies have focused on the prognostic significance of LINC00649 in AML, which we aim to investigate in this present study. Methods We compared the expression level of LINC00649 between AML patients and healthy controls. The Kaplan-Meier curves of AML patients expressing high versus low level of LINC00649 was performed. The LINC00649 correlated genes/miRNAs/lncRNAs and methylation CpG sites were screened by Pearson correlation analysis with R (version 3.6.0), using TCGA-LAML database. The LINC00649 associated ceRNA network was established using lncBase 2.0 and miRWalk 2.0 online tools, combining results from correlation analysis. Finally, a prediction model was constructed using LASSO-Cox regression. Results LINC00649 was underexpressed in bone marrow of AML group than that in healthy control group. The patients of LINC00649-low group have significantly inferior PFS and OS. A total of 154 mRNAs, 31 miRNAs, 28 lncRNAs and 1590 methylated CpG sites were identified to be significantly correlated with LINC00649. Furthermore, the network of ceRNA was established with 6 miRNAs and 122 mRNAs. The Lasso-Cox model fitted OS/PFS to novel prediction models, which integrated clinical factors, ELN risk stratification, mRNA/miRNA expression and methylation profiles. The analysis of time-dependent ROC for our model showed a superior AUC (AUC = 0.916 at 1 year, AUC = 0.916 at 3 years, and AUC = 0.891 at 5 years). Conclusions Low expression of LINC00649 is a potential unfavorable prognostic marker for AML patients, which requires the further validation. The analysis by LASSO-COX regression identified a novel comprehensive model with a superior diagnostic utility, which integrated clinical and genetic variables.
oncology
What problem does this paper attempt to address?
This paper aims to explore the prognostic significance of long non - coding RNA (lncRNA) LINC00649 in acute myeloid leukemia (AML). Specifically, the researchers hope to evaluate the possibility of LINC00649 as a potential marker of poor prognosis in AML by comparing the expression levels of LINC00649 between AML patients and healthy control groups and analyzing its relationship with survival rates. In addition, the study also established a LINC00649 - centered competing endogenous RNA (ceRNA) network, combined with factors such as clinical features, gene expression, and methylation status, to construct a new prediction model in order to improve the prediction accuracy of AML patient survival. ### Research Background - **AML**: AML is a common hematological malignancy, characterized by the unlimited proliferation of clonal myeloid precursor cells and the impairment of normal hematopoietic cell production. - **Prognosis**: The prognosis of AML patients varies greatly and is unsatisfactory. The 5 - year survival rate is less than 50%, and the 2 - year survival rate of elderly patients is only 20%. - **Existing prediction models**: The most widely used prognostic model at present is the updated ELN risk stratification, but the development of high - throughput technologies has provided more information about the genome, such as non - coding RNA expression and methylation profiles. ### Research Objectives - **Evaluate the prognostic value of LINC00649**: Explore the expression level of LINC00649 in AML and its relationship with patient survival rates. - **Establish a new prediction model**: Combine factors such as clinical features, gene expression, and methylation status to construct a comprehensive prediction model to improve the prediction accuracy of AML patient survival. ### Main Findings - **LINC00649 expression level**: The expression level of LINC00649 in the bone marrow of AML patients is significantly lower than that in the healthy control group. - **Survival analysis**: The progression - free survival (PFS) and overall survival (OS) of patients in the low - expression group of LINC00649 are significantly worse than those in the high - expression group. - **Related genes and miRNAs**: A total of 154 mRNAs, 31 miRNAs, 28 lncRNAs, and 1590 methylated CpG sites were identified to be significantly associated with LINC00649. - **ceRNA network**: A LINC00649 - centered ceRNA network containing 6 miRNAs and 122 mRNAs was established. - **Prediction model**: The LASSO - Cox regression model was used to integrate clinical features, gene expression, and methylation status to construct a new prediction model. The AUCs of this model at 1 year, 3 years, and 5 years are 0.916, 0.916, and 0.891 respectively, showing high prediction accuracy. ### Conclusions - **Low expression of LINC00649**: It is a potential poor - prognosis marker for AML patients and needs further verification. - **New prediction model**: Through LASSO - Cox regression analysis, clinical and genetic variables were integrated to establish a new model with high diagnostic utility.